O	0	8	Enhanced	Enhance	VBN	B-NP
O	9	12	IGF	IGF	NN	I-NP
O	12	13	-	-	HYPH	O
O	13	14	1	1	CD	B-NP
O	15	25	expression	expression	NN	I-NP
O	26	34	improves	improve	VBZ	B-VP
B-Cell	35	41	smooth	smooth	JJ	B-NP
I-Cell	42	48	muscle	muscle	NN	I-NP
I-Cell	49	53	cell	cell	NN	I-NP
O	54	65	engraftment	engraftment	NN	I-NP
O	66	71	after	after	IN	B-PP
B-Cell	72	76	cell	cell	NN	B-NP
O	77	92	transplantation	transplantation	NN	I-NP
O	92	93	.	.	.	O

O	94	97	The	The	DT	B-NP
O	98	108	functional	functional	JJ	I-NP
O	109	116	benefit	benefit	NN	I-NP
O	117	119	of	of	IN	B-PP
B-Cell	120	124	cell	cell	NN	B-NP
O	125	140	transplantation	transplantation	NN	I-NP
O	141	146	after	after	IN	B-PP
O	147	148	a	a	DT	B-NP
B-Multi-tissue_structure	149	159	myocardial	myocardial	JJ	I-NP
O	160	170	infarction	infarction	NN	I-NP
O	171	173	is	be	VBZ	B-VP
O	174	184	diminished	diminish	VBN	I-VP
O	185	187	by	by	IN	B-PP
O	188	193	early	early	JJ	B-NP
B-Cell	194	198	cell	cell	NN	I-NP
O	199	205	losses	loss	NNS	I-NP
O	205	206	.	.	.	O

O	207	210	IGF	IGF	NN	B-NP
O	210	211	-	-	HYPH	B-NP
O	211	212	1	1	CD	I-NP
O	213	221	enhances	enhance	VBZ	B-VP
B-Cell	222	226	cell	cell	NN	B-NP
O	227	240	proliferation	proliferation	NN	I-NP
O	241	244	and	and	CC	I-NP
O	245	253	survival	survival	NN	I-NP
O	253	254	.	.	.	O

O	255	257	We	We	PRP	B-NP
O	258	270	hypothesized	hypothesize	VBD	B-VP
O	271	275	that	that	IN	B-SBAR
O	276	279	IGF	IGF	NN	B-NP
O	279	280	-	-	HYPH	B-NP
O	280	281	1	1	CD	I-NP
O	281	282	-	-	HYPH	B-VP
O	282	293	transfected	transfecte	VBN	B-NP
B-Cell	294	300	smooth	smooth	JJ	I-NP
I-Cell	301	307	muscle	muscle	NN	I-NP
I-Cell	308	313	cells	cell	NNS	I-NP
O	314	315	(	(	(	O
B-Cell	315	319	SMCs	SMC	NNS	B-NP
O	319	320	)	)	)	O
O	321	326	would	would	MD	B-VP
O	327	334	enhance	enhance	VB	I-VP
B-Cell	335	339	cell	cell	NN	B-NP
O	340	348	survival	survival	NN	I-NP
O	349	352	and	and	CC	O
O	353	360	improve	improve	VB	B-VP
O	361	372	engraftment	engraftment	NN	B-NP
O	373	378	after	after	IN	B-PP
B-Cell	379	383	cell	cell	NN	B-NP
O	384	399	transplantation	transplantation	NN	I-NP
O	399	400	.	.	.	O

O	401	404	The	The	DT	B-NP
O	405	408	IGF	IGF	NN	I-NP
O	408	409	-	-	HYPH	B-NP
O	409	410	1	1	CD	I-NP
O	411	415	gene	gene	NN	I-NP
O	416	419	was	be	VBD	B-VP
O	420	431	transfected	transfecte	VBN	I-VP
O	432	436	into	into	IN	B-PP
O	437	441	male	male	JJ	B-NP
B-Cell	442	446	SMCs	SMC	NNS	I-NP
O	447	450	and	and	CC	O
O	451	459	compared	compare	VBN	B-PP
O	460	464	with	with	IN	B-PP
B-Cell	465	469	SMCs	SMC	NNS	B-NP
O	470	481	transfected	transfecte	VBN	B-VP
O	482	486	with	with	IN	B-PP
O	487	488	a	a	DT	B-NP
B-Cellular_component	489	496	plasmid	plasmid	NN	I-NP
O	497	503	vector	vector	NN	I-NP
O	504	505	(	(	(	O
O	505	511	vector	vector	NN	B-NP
O	512	519	control	control	NN	I-NP
O	519	520	)	)	)	O
O	521	524	and	and	CC	O
O	525	539	nontransfected	nontransfected	JJ	B-NP
B-Cell	540	544	SMCs	SMC	NNS	I-NP
O	545	546	(	(	(	O
B-Cell	546	550	cell	cell	NN	B-NP
O	551	558	control	control	NN	I-NP
O	558	559	)	)	)	O
O	559	560	.	.	.	O

O	561	564	IGF	IGF	NN	B-NP
O	564	565	-	-	HYPH	B-NP
O	565	566	1	1	CD	I-NP
O	567	571	mRNA	mRNA	NN	I-NP
O	572	573	(	(	(	O
O	573	574	n	n	NN	B-NP
O	574	575	=	=	SYM	B-VP
O	575	577	10	10	CD	B-NP
O	577	578	/	/	SYM	I-NP
O	578	583	group	group	NN	I-NP
O	583	584	)	)	)	O
O	585	588	and	and	CC	O
O	589	596	protein	protein	NN	B-NP
O	597	603	levels	level	NNS	I-NP
O	604	605	(	(	(	O
O	605	606	n	n	NN	B-NP
O	606	607	=	=	SYM	B-VP
O	607	608	6	6	CD	B-NP
O	608	609	/	/	SYM	I-NP
O	609	614	group	group	NN	I-NP
O	614	615	)	)	)	O
O	616	620	were	be	VBD	B-VP
O	621	627	higher	high	JJR	B-ADJP
O	628	629	(	(	(	O
O	629	630	P	P	NN	B-NP
O	632	636	less	less	JJR	B-NP
O	637	641	than	than	IN	I-NP
O	642	643	0	0	CD	I-NP
O	643	644	.	.	.	I-NP
O	644	646	05	05	CD	I-NP
O	647	650	for	for	IN	B-PP
O	651	654	all	all	DT	B-NP
O	655	661	groups	group	NNS	I-NP
O	661	662	)	)	)	O
O	663	665	at	at	IN	B-PP
O	666	667	3	3	CD	B-NP
O	667	668	,	,	,	I-NP
O	669	670	7	7	CD	I-NP
O	670	671	,	,	,	O
O	672	675	and	and	CC	O
O	676	678	14	14	CD	B-NP
O	679	683	days	day	NNS	I-NP
O	684	692	compared	compare	VBN	B-PP
O	693	697	with	with	IN	B-PP
O	698	706	controls	control	NNS	B-NP
O	706	707	.	.	.	O

O	708	712	VEGF	VEGF	NN	B-NP
O	713	716	was	be	VBD	B-VP
O	717	721	also	also	RB	I-VP
O	722	731	increased	increase	VBN	I-VP
O	732	734	in	in	IN	B-PP
O	735	743	parallel	parallel	NN	B-NP
O	744	746	to	to	TO	B-PP
O	747	755	enhanced	enhance	VBN	B-NP
O	756	759	IGF	IGF	NN	I-NP
O	759	760	-	-	HYPH	O
O	760	761	1	1	CD	B-NP
O	762	772	expression	expression	NN	I-NP
O	772	773	.	.	.	O

O	774	777	IGF	IGF	NN	B-NP
O	777	778	-	-	HYPH	B-NP
O	778	779	1	1	CD	I-NP
O	779	780	-	-	HYPH	I-NP
O	780	791	transfected	transfecte	VBN	I-NP
B-Cell	792	797	cells	cell	NNS	I-NP
O	798	810	demonstrated	demonstrate	VBD	B-VP
O	811	818	greater	great	JJR	B-NP
B-Cell	819	823	cell	cell	NN	I-NP
O	824	837	proliferation	proliferation	NN	I-NP
O	837	838	,	,	,	O
O	839	849	stimulated	stimulate	VBN	B-VP
O	850	862	angiogenesis	angiogenesis	NN	B-NP
O	862	863	,	,	,	O
O	864	867	and	and	CC	O
O	868	877	decreased	decrease	VBD	B-VP
O	878	885	caspase	caspase	NN	B-NP
O	885	886	-	-	HYPH	B-NP
O	886	887	3	3	CD	I-NP
O	888	896	activity	activity	NN	I-NP
O	897	902	after	after	IN	B-PP
O	903	912	simulated	simulated	JJ	B-NP
O	913	921	ischemia	ischemia	NN	I-NP
O	922	925	and	and	CC	O
O	926	937	reperfusion	reperfusion	NN	B-NP
O	938	939	(	(	(	O
O	939	940	P	P	NN	B-NP
O	942	946	less	less	JJR	B-NP
O	947	951	than	than	IN	I-NP
O	952	953	0	0	CD	I-NP
O	953	954	.	.	.	I-NP
O	954	956	05	05	CD	I-NP
O	957	960	for	for	IN	B-PP
O	961	964	all	all	DT	B-NP
O	965	971	groups	group	NNS	I-NP
O	972	980	compared	compare	VBN	B-PP
O	981	985	with	with	IN	B-PP
O	986	992	vector	vector	NN	B-NP
O	993	995	or	or	CC	I-NP
B-Cell	996	1000	cell	cell	NN	I-NP
O	1001	1009	controls	control	NNS	I-NP
O	1009	1010	)	)	)	O
O	1010	1011	.	.	.	O

O	1012	1013	A	A	DT	B-NP
O	1014	1021	uniform	uniform	JJ	I-NP
B-Multi-tissue_structure	1022	1026	left	left	JJ	I-NP
I-Multi-tissue_structure	1027	1038	ventricular	ventricular	JJ	I-NP
O	1039	1045	injury	injury	NN	I-NP
O	1046	1049	was	be	VBD	B-VP
O	1050	1058	produced	produce	VBN	I-VP
O	1059	1061	in	in	IN	B-PP
O	1062	1068	female	female	JJ	B-NP
O	1069	1073	rats	rat	NNS	I-NP
O	1074	1079	using	use	VBG	B-VP
O	1080	1081	a	a	DT	B-NP
O	1082	1091	cryoprobe	cryoprobe	NN	I-NP
O	1091	1092	.	.	.	O

O	1093	1098	Three	Three	CD	B-NP
O	1099	1104	weeks	week	NNS	I-NP
O	1105	1110	later	later	RB	B-ADVP
O	1110	1111	,	,	,	O
O	1112	1113	2	2	CD	B-NP
O	1114	1115	x	x	CC	I-NP
O	1116	1118	10	10	CD	I-NP
O	1118	1119	(	(	(	O
O	1119	1120	6	6	CD	B-NP
O	1120	1121	)	)	)	O
B-Cell	1122	1127	cells	cell	NNS	B-NP
O	1128	1132	from	from	IN	B-PP
O	1133	1138	three	three	CD	B-NP
O	1139	1145	groups	group	NNS	I-NP
O	1146	1150	were	be	VBD	B-VP
O	1151	1160	implanted	implant	VBN	I-VP
O	1161	1165	into	into	IN	B-PP
O	1166	1169	the	the	DT	B-NP
B-Pathological_formation	1170	1174	scar	scar	NN	I-NP
O	1174	1175	.	.	.	O

O	1176	1179	One	One	CD	B-NP
O	1180	1184	week	week	NN	I-NP
O	1185	1190	later	later	RB	B-ADVP
O	1190	1191	,	,	,	O
O	1192	1195	IGF	IGF	NN	B-NP
O	1195	1196	-	-	HYPH	B-NP
O	1196	1197	1	1	CD	I-NP
O	1197	1198	-	-	HYPH	I-NP
O	1198	1209	transfected	transfecte	VBN	I-NP
B-Cell	1210	1214	SMCs	SMC	NNS	I-NP
O	1215	1218	had	have	VBD	B-VP
O	1219	1228	increased	increase	VBN	I-VP
B-Multi-tissue_structure	1229	1239	myocardial	myocardial	JJ	B-NP
O	1240	1243	IGF	IGF	NN	I-NP
O	1243	1244	-	-	HYPH	B-NP
O	1244	1245	1	1	CD	I-NP
O	1246	1249	and	and	CC	I-NP
O	1250	1254	VEGF	VEGF	NN	I-NP
O	1255	1261	levels	level	NNS	I-NP
O	1261	1262	,	,	,	O
O	1263	1272	increased	increase	VBN	B-NP
O	1273	1277	Bcl2	Bcl2	NN	I-NP
O	1278	1288	expression	expression	NN	I-NP
O	1288	1289	,	,	,	O
O	1290	1297	limited	limited	JJ	B-NP
B-Cell	1298	1302	cell	cell	NN	I-NP
O	1303	1312	apoptosis	apoptosis	NN	I-NP
O	1312	1313	,	,	,	O
O	1314	1317	and	and	CC	O
O	1318	1326	enhanced	enhance	VBN	B-NP
B-Multi-tissue_structure	1327	1333	vessel	vessel	NN	I-NP
O	1334	1343	formation	formation	NN	I-NP
O	1344	1346	in	in	IN	B-PP
O	1347	1350	the	the	DT	B-NP
B-Pathological_formation	1351	1361	myocardial	myocardial	JJ	I-NP
I-Pathological_formation	1362	1366	scar	scar	NN	I-NP
O	1367	1375	compared	compare	VBN	B-PP
O	1376	1380	with	with	IN	B-PP
O	1381	1384	the	the	DT	B-NP
O	1385	1388	two	two	CD	I-NP
O	1389	1396	control	control	NN	I-NP
O	1397	1403	groups	group	NNS	I-NP
O	1404	1405	(	(	(	O
O	1405	1406	P	P	NN	B-NP
O	1408	1412	less	less	JJR	B-NP
O	1413	1417	than	than	IN	I-NP
O	1418	1419	0	0	CD	I-NP
O	1419	1420	.	.	.	I-NP
O	1420	1422	05	05	CD	I-NP
O	1423	1426	for	for	IN	B-PP
O	1427	1430	all	all	DT	B-NP
O	1431	1437	groups	group	NNS	I-NP
O	1437	1438	)	)	)	O
O	1438	1439	.	.	.	O

O	1440	1443	The	The	DT	B-NP
O	1444	1454	proportion	proportion	NN	I-NP
O	1455	1457	of	of	IN	B-PP
B-Cell	1458	1462	SMCs	SMC	NNS	B-NP
O	1463	1472	surviving	survive	VBG	B-VP
O	1473	1475	in	in	IN	B-PP
O	1476	1479	the	the	DT	B-NP
O	1480	1489	implanted	implant	VBN	I-NP
O	1490	1496	region	region	NN	I-NP
O	1497	1500	was	be	VBD	B-VP
O	1501	1508	greater	great	JJR	B-ADJP
O	1509	1510	(	(	(	O
O	1510	1511	P	P	NN	B-NP
O	1513	1517	less	less	JJR	B-NP
O	1518	1522	than	than	IN	I-NP
O	1523	1524	0	0	CD	I-NP
O	1524	1525	.	.	.	I-NP
O	1525	1527	05	05	CD	I-NP
O	1527	1528	)	)	)	O
O	1529	1531	in	in	IN	B-PP
O	1532	1535	the	the	DT	B-NP
O	1536	1539	IGF	IGF	NN	I-NP
O	1539	1540	-	-	HYPH	B-NP
O	1540	1541	1	1	CD	I-NP
O	1541	1542	-	-	HYPH	I-NP
O	1542	1553	transfected	transfecte	VBN	I-NP
O	1554	1559	group	group	NN	I-NP
O	1560	1564	than	than	IN	B-PP
O	1565	1567	in	in	IN	B-PP
O	1568	1571	the	the	DT	B-NP
O	1572	1578	vector	vector	NN	I-NP
O	1579	1581	or	or	CC	I-NP
B-Cell	1582	1586	cell	cell	NN	I-NP
O	1587	1595	controls	control	NNS	I-NP
O	1595	1596	.	.	.	O

O	1597	1601	Gene	Gene	NN	B-NP
O	1602	1613	enhancement	enhancement	NN	I-NP
O	1614	1618	with	with	IN	B-PP
O	1619	1622	IGF	IGF	NN	B-NP
O	1622	1623	-	-	HYPH	B-NP
O	1623	1624	1	1	CD	I-NP
O	1625	1633	improved	improve	VBD	B-VP
B-Cell	1634	1639	donor	donor	NN	B-NP
I-Cell	1640	1644	cell	cell	NN	I-NP
O	1645	1658	proliferation	proliferation	NN	I-NP
O	1658	1659	,	,	,	O
O	1660	1668	survival	survival	NN	B-NP
O	1668	1669	,	,	,	O
O	1670	1673	and	and	CC	O
O	1674	1685	engraftment	engraftment	NN	B-NP
O	1686	1691	after	after	IN	B-PP
B-Cell	1692	1696	cell	cell	NN	B-NP
O	1697	1712	transplantation	transplantation	NN	I-NP
O	1712	1713	,	,	,	O
O	1714	1721	perhaps	perhaps	RB	B-VP
O	1722	1730	mediated	mediate	VBN	I-VP
O	1731	1733	by	by	IN	B-PP
O	1734	1742	enhanced	enhance	VBN	B-NP
O	1743	1755	angiogenesis	angiogenesis	NN	I-NP
O	1756	1759	and	and	CC	O
O	1760	1767	reduced	reduce	VBN	B-NP
O	1768	1777	apoptosis	apoptosis	NN	I-NP
O	1777	1778	.	.	.	O

